EBITDA: Income before interest, taxes, depreciation and amortization.
Promis Neurosciences (PMN) had EBITDA of $-40.17M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-39.72M |
|
-- |
|
-- |
|
$40.17M |
|
$-40.17M |
|
$0.45M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-39.72M |
|
$-40.17M |
|
|
EBITDA |
$-40.17M |
1.76M |
|
1.76M |
|
$-22.61 |
|
$-22.61 |
|
| Balance Sheet Financials | |
$9.18M |
|
-- |
|
-- |
|
$9.18M |
|
$10.41M |
|
-- |
|
$0.03M |
|
$10.44M |
|
$-1.26M |
|
$-1.26M |
|
$-1.26M |
|
2.15M |
|
| Cash Flow Statement Financials | |
$-28.12M |
|
$-0.00M |
|
$20.94M |
|
$13.29M |
|
$6.12M |
|
$-7.17M |
|
$0.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
3155.85% |
|
3155.84% |
|
-432.56% |
|
3155.84% |
|
$-0.58 |
|
$-16.00 |
|
$-16.00 |
|